


NUDT5/14 antagonist 1

Cat. No.:	HY-158318
Molecular Formula:	C ₂₃ H ₂₄ N ₆ O
Molecular Weight:	400.48
Target:	DNA/RNA Synthesis
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	NUDT5/14 antagonist 1 (Compound 9) is a selective, dual antagonist for nucleotide diphosphate kinase NUDT5 and NUDT14, with IC ₅₀ of 0.27 and 0.16 μM, respectively. NUDT5/14 antagonist 1 binds to Bruton's tyrosine kinase (BTK) with an IC ₅₀ of 0.377 μM ^[1] .									
IC₅₀ & Target	IC ₅₀ : 0.27 μM (NUDT5), 0.16 μM (NUDT14)									
In Vitro	<p>NUDT5/14 antagonist 1 (>10 μM, 72 h) exhibits no cytotoxicity in cancer cells BT-474^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>BT-474</td> </tr> <tr> <td>Concentration:</td> <td>>10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>72 h</td> </tr> <tr> <td>Result:</td> <td>Maintained cell viability with concentration of 10 μM.</td> </tr> </table>		Cell Line:	BT-474	Concentration:	>10 μM	Incubation Time:	72 h	Result:	Maintained cell viability with concentration of 10 μM.
Cell Line:	BT-474									
Concentration:	>10 μM									
Incubation Time:	72 h									
Result:	Maintained cell viability with concentration of 10 μM.									

REFERENCES

[1]. Balıkcı E, et al., Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist. J Med Chem. 2024 May 9;67(9):7245-7259.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA